Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $800 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Alethia Young has reiterated a Neutral rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained a price target of $800.
September 21, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regeneron Pharmaceuticals has been reiterated with a Neutral rating and a price target of $800 by Cantor Fitzgerald.
The reiteration of a Neutral rating indicates that the analyst believes the stock will perform in line with the market average. This could mean that there are no significant catalysts expected to drive the stock price significantly higher or lower in the short term. The maintained price target of $800 suggests that the analyst believes this is the fair value of the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100